doi:10.3969/j.issn.1673-8640.2015.02.024

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 10

[1]	年华,褚云卓,王倩.ICU与非ICU病房致病细菌谱及耐药分析[J].中国公共卫生,2007,23(12):1516-1517.
[2]	陆燕珍,吕波,张明真,等.细菌性肺炎患儿血清CRP、ESR、WBC的变化及临床意义[J].中国医药导报,2010,31(9):27-28.
[3]	温柏平. hs-CRP鉴别儿童急性呼吸道感染的临床价值[J].放射免疫学杂志,2009,22(2):177-178.
[4]	付圆. 在儿童感染性疾病早期进行CRP检测的临床意义[J].中国现代医生,2012,50(31):139-140.
[5]	何静,卢卫国. 联合测定血清PCT与CRP对感染性疾病的诊断价值[J].检验医学与临床,2012,9(15):1904-1905.
[6]	汤瑾,许静,王坚镪,等. 降钙素原联合C反应蛋白检测在血流感染早期临床诊断的应用[J]. 检验医学,2013,28(8):662-665.
[7]	戴佩佩,裘晓乐,徐克. 降钙素原与C反应蛋白联合检测在细菌感染中的应用[J]. 检验医学,2010,25(11):858-860.
[8]	邵良荣,邵杰. 肺部感染患者血清降钙素原检测的临床应用[J]. 检验医学,2012,27(12):1093-1094.
[9]	鲁君艳,姜志刚,周维新,等. 血清降钙素原在儿童社区获得性肺炎诊断中的意义[J]. 检验医学,2013,28(1):40-43.
[10]	王玉梅,孙丽娟,王善菊.血清PCT和CRP对社区获得性肺炎的诊断价值[J].放射免疫学杂志,2011,24(4):447-449.

组别	例数	WBC (×10⁹/L)	PCT (ng/mL)	CRP (mg/L)
感染组	52	13.68	6.86	68.51
非感染组	46	6.11^*	0.43^*	2.31^*

组别	例数	WBC (×10⁹/L)	PCT (ng/mL)	CRP (mg/L)
感染组	52	13.68	6.86	68.51
非感染组	46	6.11^*	0.43^*	2.31^*

组别	例数	PCT(ng/mL)				阳性率(%)
组别	例数	≤0.5		>0.5~2.0	>2.0~10.0	>10.0
感染组	52	1	17	24	10	98.08
非感染组	46	37	9	0	0	19.57^*

组别	例数	PCT(ng/mL)				阳性率(%)
组别	例数	≤0.5		>0.5~2.0	>2.0~10.0	>10.0
感染组	52	1	17	24	10	98.08
非感染组	46	37	9	0	0	19.57^*

组别	例数	CRP(mg/L)			WBC(×10⁹/L)
组别	例数	≤6	>6	阳性率(%)	≤10	>10	阳性率(%)
感染组	52	0	52	100.00	24	28	53.85
非感染组	46	35	11	23.91*	43	3	6.52^*

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 10

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.